Navigation Links
Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
Date:3/28/2011

NEW YORK, March 28, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) (the "Company") today announced that two abstracts on KRX-0401 (perifosine) will be presented at the upcoming 102nd annual meeting of the American Association for Cancer Research (AACR) to be held in Orlando, Florida, from April 2-6, 2011. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma. Both of these Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA, and with Fast Track designations obtained for both indications. Perifosine is also in Phase 1 and 2 clinical development for several other tumor types.Sunday, April 3, 2011Abstract #640:

"The Akt inhibitor Perifosine strongly enhances the antitumor and antivascular activity of CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)", A. Giacomini, S. L. Locatelli, M. Righi, L. Cleris, P.D. Longoni, M. Milanesi, M. Francolini, M. Magni, M. Di Nicola, A. M. Gianni, C. Carlo-Stella.Date and time:

Sunday, April 3, 2011, 1:00-5:00 p.m. Eastern (Exhibit Hall A4-C)Poster Session ID:

Cellular and Molecular Biology 27Poster Section:

27 Poster Board:

14Monday, April 4, 2011Abstract #1965:

"Antitumor activity of novel Akt inhibitor, perifosine in gastric cell lines.", Tae Soo Kim, Hyo Song Kim, Bo Ram Kwan, Chan Hee Park Park, Hei-Cheul Jeung Jeung, Woo Ick Jang, Juergen Engel, Hyun Cheol Chung, Jae Kyung Roh, Sun Young Rha.Date and time:

Monday, April 4, 2011, 1:00-5:00 p.m. Eastern (Exhibit Hall A4-C)Poster Session ID:

Cellular and Molecular Biology 27Poster Section:

2Poster Board:

5The above abstracts are currently available online for viewing through the AACR 2011 Meeting website at: http://www.aacr.org/home/scientists/meetings--workshops/aacr-102nd-annual-meeting-2011/abstracts.aspx

KRX-0401 (perifosine) is in-licensed by Keryx from AEterna Zentaris Inc. in the United States, Canada and Mexico.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

Cautionary StatementSome of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for KRX-0401 (perifosine), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for KRX-0401 (perifosine); the risk that the data (both safety and efficacy) from ongoing clinical trials will not coincide with the data analyses from prior pre-clinical and clinical trials previously reported by the Company; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website and the AACR website is not incorporated by reference into this press release and is included for reference purposes only.

KERYX CONTACT:Lauren FischerDirector - Investor RelationsKeryx Biopharmaceuticals, Inc.Tel: 212.531.5965E-mail: lfischer@keryx.com
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
3. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
4. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
5. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
6. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
7. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
8. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
9. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
10. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
11. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)...  Sequent Medical, Inc. announced today that it has ... safety and effectiveness of the WEB™ Aneurysm Embolization System ... Prof Laurent Spelle , MD, Head of Neuroradiology ... and Principal Investigator of the CLARYS study, ... and Germany.  Although patients with ruptured aneurysms have ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... WILMINGTON, North Carolina , 12 februari ... Laboratories, Inc. (AAI/CML), een toonaangevende leverancier van ... farmaceutische en biotechnologische industrieën, kondigt vandaag een ... en mogelijkheden op haar locatie in ... in vraag heeft geleid tot meerdere recente ...
Breaking Medicine Technology:
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... ... Prater Eye Center becomes the first in the area to offer AngioPlex™ Optical ... signs of retinal disease, such as macular degeneration, diabetic retinopathy, and other vascular ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... Many individuals ... of protein for a multitude of reasons. IsoPasta by Isolator Fitness has delved ... it once more, but without the high-carb repercussions. IsoPasta has 30 grams of ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical Holdings, ... gift of a VeinViewer® Vision vein finder for the nursing school ... an IV and draw blood, combining technology with traditional technique. , “VeinViewer is ...
(Date:2/12/2016)... CA (PRWEB) , ... February 12, 2016 , ... According ... hernia surgeries are beginning to account for a significant portion of hernia repairs throughout ... Towfigh of the Beverly Hills Hernia Center notes that this trend has not only ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – hosted over 250 members of South Florida’s philanthropic community at its 10th ...
Breaking Medicine News(10 mins):